



ATTORNEY'S DOCKET CS-120  
MAIL STOP AF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: ) Group Art Unit: 1642  
                          ) )  
TALOR                  ) Examiner: Gary B. Nickol  
                          ) )  
Serial No. 10/611,914 ) )  
                          ) )  
Filed: July 03, 2003   ) )

For: **A METHOD OF PRE-SENSITIZING CANCER PRIOR TO TREATMENT WITH RADIATION AND/OR CHEMOTHERAPY AND A NOVEL CYTOKINE MIXTURE**

Appendix A

Please amend the claims according to 37 C.F.R. § 1.121 concerning a manner for making claim amendments.

Claims 1-23 (Canceled)

24. (Previously presented) A serum-free and mitogen-free cytokine mixture, comprising specific ratios of cytokines selected from the group of IL-1 $\beta$ , TNF- $\alpha$ , IFN- $\gamma$  and GM-CSF to Interleukin-2 (IL-2) as follows:

IL-1 $\beta$  to IL-2 at a ratio range of 0.4 - 1.5;

TNF- $\alpha$  to IL-2 at a ratio range of 3.2 - 11.3;

IFN- $\gamma$  to IL-2 at a ratio range of 1.5 - 10.9; and

GM-CSF to IL-2 at a ratio range of 2.2 - 4.8

with the proviso that IL-12 is present in only trace

quantities.

25. (Previously presented) The serum-free and mitogen-free cytokine mixture of claim 24, wherein said specific ratios of cytokines are as follows:

IL-1 $\beta$  to IL-2 at a ratio range of 0.6 to 0.8;  
TNF- $\alpha$  to IL-2 at a ratio range of 7.7 to 10.9;  
IFN- $\gamma$  to IL-2 at a ratio range of 4.9 to 7.1; and  
GM-CSF to IL-2 at a ratio range of 3.5 to 4.5.

26. (Previously presented) A pharmaceutical composition for use in treating cancer, comprising specific ratios of cytokines selected from the group of IL-1 $\beta$ , TNF- $\alpha$ , IFN- $\gamma$  and GM-CSF to Interleukin-2 (IL-2) as follows:

IL-1 $\beta$  to IL-2 at a ratio range of 0.4 - 1.5;  
TNF- $\alpha$  to IL-2 at a ratio range of 3.2 - 11.3;  
IFN- $\gamma$  to IL-2 at a ratio range of 1.5 - 10.9;  
GM-CSF to IL-2 at a ratio range of 2.2 - 4.8,  
with the proviso that IL-12 is present in only trace quantities and  
optionally in combination with a pharmaceutically

acceptable excipient, carrier or additive.

27. (Previously presented) The pharmaceutical composition of claim 26, wherein said specific ratios of cytokines are as follows:

IL-1 $\beta$  to IL-2 at a ratio range of 0.6 to 0.8;  
TNF- $\alpha$  to IL-2 at a ratio range of 7.7 to 10.9;  
IFN- $\gamma$  to IL-2 at a ratio range of 4.9 to 7.1; and  
GM-CSF to IL-2 at a ratio range of 3.5 to 4.5.

Claims 28-41 (Canceled)